维持性血透患者每4周与每6周常规化验的频率比较:一项质量改进项目
该回顾性中断时间序列研究在加拿大安大略省一家三级医院进行,纳入350至400例维持性血透成人患者,于2014年3月24日将常规血检间隔从4周改为6周。结果显示血红蛋白(10-12g/dL)和磷酸盐(2.5-4.6mg/dL)达标比例保持稳定(平均60%和46%),血透单元死亡率稳定(平均每月2%),每患者年节省85加元,项目范围节省35,000加元。
要点
- 将常规血检间隔从4周延长至6周后,血红蛋白和磷酸盐达标率保持稳定。
- 血透单元死亡率保持稳定,平均每月2%。
- 延长血检间隔每患者年节省85加元,项目范围节省35,000加元。
核心结论
- 将常规血检间隔从4周改为6周后,贫血和CKD-MBD达标表现未改变,且血检减少与实验室成本节省相关。
研究设计与样本
- 回顾性中断时间序列研究,时间范围为2012年6月1日至2015年12月31日。
- 研究地点为加拿大安大略省一家三级医院,为350至400例维持性血透成人患者提供服务。
- 质量改进活动为2014年3月24日全院范围内将常规血检间隔从4周改为6周。
主要发现
- 血红蛋白(10-12g/dL)达标比例保持稳定,平均为60%。
- 磷酸盐(2.5-4.6mg/dL)达标比例保持稳定,平均为46%。
- 血透单元死亡率保持稳定,平均每月2%。
- 将血检频率降至每6周与每患者年节省85加元相关,对应项目范围节省35,000加元。
关键数值与推荐
- 血红蛋白目标值为10-12g/dL,磷酸盐目标值为2.5-4.6mg/dL。
临床怎么用
- 对于维持性血透患者,可考虑将常规血检间隔从4周延长至6周以节省实验室成本,同时需监测贫血和CKD-MBD指标。
局限性
- 因使用血透单元汇总数据,未进行病例组合调整。
- 缺乏住院和输血数据,限制了对患者护理全部成本的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Few data exist revealing how the frequency of routine blood work for patients on maintenance hemodialysis therapy affects patient outcomes and the costs of care. Our objective was to determine the effect of changing the frequency of blood work from 4- to 6-week intervals on the achievement of anemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) targets. STUDY DESIGN: Retrospective interrupted time series from June 1, 2012, to December 31, 2015. SETTING & PARTICIPANTS: Tertiary hospital in Ontario, Canada, that provides maintenance hemodialysis therapy to 350 to 400 adult patients. QUALITY IMPROVEMENT ACTIVITIES: Institution-wide switch of the interval for routine blood work from 4 to 6 weeks on March 24, 2014. OUTCOMES: Achievement of recommended hemoglobin and phosphate level targets. Cost savings attributable to a change in frequency of blood work for hemoglobin, ferritin, iron saturation, calcium, and phosphate comparing 252-day periods under each testing frequency condition. ANALYTICAL APPROACH: Statistical process control to analyze variation in the clinical outcomes. RESULTS: The proportion of patients who achieved hemoglobin (10-12g/dL) and phosphate (2.5-4.6mg/dL) targets remained stable (average of 60% and 46%, respectively), with no measurements beyond 3 standard deviations from the mean. The hemodialysis unit mortality rate also remained stable (average of 2% per month). Reducing blood work frequency to every 6 weeks was associated with a saving of $85 per patient-year, corresponding to a program-wide savings of $35,000. LIMITATIONS: No case-mix adjustment due to use of aggregate hemodialysis unit data, and absence of data for hospitalizations and transfusions limiting assessment of the full cost of patient care. CONCLUSIONS: After switching the frequency of routine blood work from 4- to 6-week intervals, performance on anemia and CKD-MBD targets did not change and the reduction in blood work was associated with laboratory cost savings. Reducing the frequency of blood work may represent an opportunity for hemodialysis providers to devote greater efforts toward other care elements that better improve patient outcomes.
引用
- Silver SA, Alaryni A, Alghamdi A, et al. Routine Laboratory Testing Every 4 Versus Every 6 Weeks for Patients on Maintenance Hemodialysis: A Quality Improvement Project. Am J Kidney Dis. 2018. PMID: 30598347. doi:10.1053/j.ajkd.2018.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。